Frail Elderly Syndrome Clinical Trial
— AFFIRMOfficial title:
AFFIRM: A Phase 2 Randomized, Placebo-Controlled Study of Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women
Verified date | February 2024 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a pilot study to evaluate whether targeting inflammation will help reduce markers of insulin resistance inflammation, bone resorption and physical dysfunction in elderly women with gait disturbance. Positive results of this study would lead to the development of a larger clinical trial examining the effects of this intervention on age-related dysfunction.
Status | Enrolling by invitation |
Enrollment | 40 |
Est. completion date | October 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 70 Years and older |
Eligibility | Inclusion Criteria - Healthy postmenopausal women - Age = 70 years Exclusion Criteria - Abnormality in any of the screening laboratory studies (see below) - Presence of significant liver or renal disease - Malignancy (including myeloma) - Malabsorption - Hypoparathyroidism - Hyperparathyroidism - Acromegaly - Cushing's syndrome - Hypopituitarism - Gastric bypass/reduction - Malabsorption issues - Crohn's - Myopathies (increased or low calcium, vitamin D deficiency, elevated creatine kinase or ESR) - If diabetic AND on sulfonylureas (like glipizide, glimepiride, glyburide), SGLT2 inhibitors (like dapagliflozin and empagliflozin), or insulin - Undergoing treatment with any medications that affect bone turnover, including the following: - adrenocorticosteroids (> 3 months at any time or > 10 days within the previous yr), anticonvulsant therapy (within the previous year), - pharmacological doses of thyroid hormone (causing decline of thyroid stimulating hormone below normal), - calcium supplementation of > 1200 mg/d (within the preceding 3 months), - bisphosphonates (within the past 3 yrs), - denosumab, - estrogen (E) therapy or treatment with a selective E receptor modulator, or teriparatide (within the past yr). - Subjects with a fracture within the past year - Subjects taking potentially senolytic agents within the last year: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax - Subjects currently taking drugs that induce cellular senescence: alkylating agents, anthracyclines, platins, other chemotherapy - QTc >450 msec - Inability to provide informed consent - Total bilirubin >2X upper limit - Inability to tolerate oral medication - eGFR < 15 ml/ min/ 1.73 m2 - Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.) - Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals (fluconazole, miconazole, voriconazole, itraconazole), Macrolides (clarithromycin, erythromycin), Antivirals (nelfinavir, indinavir, saquinavir, ritonavir, elbasvir/grazoprevir), Rifampin - Subjects taking proton pump inhibitors who are unable or unwilling to reduce or hold therapy prior to and during the 2-day Fisetin dosing - Subjects taking the following other drugs if they cannot be held for at least 2 days before and during administration of Fisetin: digoxin, lithium, all statins, repaglidine, bosentan, gemfibrozil, olmesartan, enalapril, valsartan, methotrexate, corticosteroids, thyroid hormones, eluxadoline, eltrombopag, nitroglycerin, pioglitazone, glyburide, enzalutamide, ezetimibe, colchicine, imatinib, cyclosporine, tacolimus, sirolimus, carbamazepine, flecainide, phenytoin, phenobarbital, rifampicin, theophylline, warfarin, heparin, full dose ASA, clopidogrel, celecoxib, desipramine, thioridazine, venlafaxine, tizanidine, atomoxetine, voriconazole, citalopram, diazepam, escitalopram, propranolol, clozapine, cyclobenzaprine, mexiletine, olanzapine, ondansetron, riluzole - In order to ensure vitamin D sufficiency, we will also exclude subjects with serum 25-hydroxyvitamin D levels of < 20 ng/ml. |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Improved 6 minute walk | Improved gait speed | One Month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04792983 -
Cognition and the Immunology of Postoperative Outcomes
|
||
Completed |
NCT03271112 -
Frailty Prevention in Elders From Reunion Island
|
N/A | |
Recruiting |
NCT03141866 -
Seated Physical Activity in Ageing
|
N/A | |
Completed |
NCT03180606 -
Enhanced Primary Care for Elderly
|
||
Recruiting |
NCT05940779 -
Relationship Between the Risk of Falls and Frailty, and the Effect of a Physical Exercise Program on These Conditions in the Elderly: a Randomized Crossover Clinical Trial.
|
N/A | |
Active, not recruiting |
NCT05961319 -
Smart Home Technologies for Assessing and Monitoring Frailty in Older Adults
|
||
Recruiting |
NCT04518423 -
Prevalence, Determinants and Natural History of Frailty and Pre-frailty in Elderly People
|
||
Completed |
NCT03883425 -
Frailty and Complexity Among Home Service Recipients
|
||
Recruiting |
NCT03657940 -
Impact of a Multicomponent Exercise Program on Functional Capacity in Frail Aged Participants With Cognitive Decline
|
N/A | |
Completed |
NCT03724461 -
Effects of Resistance Training With High vs. Light-moderate Loads on Muscle-tendon Function in the Elderly
|
N/A | |
Withdrawn |
NCT03176030 -
Fortified Foods in Older Inpatients
|
||
Completed |
NCT04615533 -
Validity Reliability of FrailBESTest in Older Adults
|
||
Recruiting |
NCT04238494 -
Muscle Multi-parametric NMR Imaging Development in Aged People With Sarcopenia or Frailty Syndrome; CLINical Study
|
N/A | |
Active, not recruiting |
NCT06079762 -
AGE SELF CARE: Promoting Healthy Aging Through a Group Visit Program
|
N/A | |
Not yet recruiting |
NCT06019390 -
eHealth for Screening Health Risks in Home-Based Older Adults: A Prospective Study
|
N/A | |
Recruiting |
NCT03534765 -
Frailty and Sarcopenia Outcomes in Emergency General Surgery
|
||
Active, not recruiting |
NCT03721471 -
Outcome of Very Old Patients Admitted for Elective Major Surgery, the Effect of Frailty
|
||
Completed |
NCT03688932 -
Effects of WBV Associated With IMT on Functionality
|
N/A | |
Completed |
NCT03689322 -
Effects of WBV Associated With IMT on Inflammatory Markers, Body Composition, Muscle Strength and Thickness
|
N/A | |
Recruiting |
NCT03068299 -
Effects of Music and Dance on Cognition, Frailty, and Burden in Elderly Caregivers Living in Rural Communities
|
N/A |